Adage Capital Partners’s Dyne Therapeutics DYN Stock Holding History

Adage Capital Partners’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.1M	Sell	1,000,000 -4,172,000	-81%	-$71.9M	0.03%	503
2025 Q4	$101M	Buy	5,172,000 +1,618,000	+46%	+$30.6M	0.15%	127
2025 Q3	$45M	Buy	3,554,000 +363,000	+11%	+$4.14M	0.07%	259
2025 Q2	$30.4M	Buy	+3,191,000	New	+$35.1M	0.05%	348
2025 Q1	–	Sell	-1,950,000	Closed	-$45.9M	–	868
2024 Q4	$45.9M	Sell	1,950,000 -452,972	-19%	-$13.4M	0.08%	233
2024 Q3	$86.3M	Sell	2,402,972 -925,028	-28%	-$36.8M	0.15%	134
2024 Q2	$117M	Buy	3,328,000 +1,003,000	+43%	+$29.1M	0.22%	84
2024 Q1	$66M	Buy	+2,325,000	New	+$52.6M	0.12%	179
2023 Q3	–	Sell	-100,000	Closed	-$1.13M	–	888
2023 Q2	$1.13M	Sell	100,000 -500,000	-83%	-$5.9M	﹤0.01%	765
2023 Q1	$6.91M	Buy	600,000 +200,000	+50%	+$2.6M	0.02%	673
2022 Q4	$4.64M	Sell	400,000 -50,000	-11%	-$579K	0.01%	757
2022 Q3	$5.71M	Sell	450,000 -120,000	-21%	-$1.38M	0.01%	761
2022 Q2	$3.92M	Sell	570,000 -180,000	-24%	-$1.24M	0.01%	828
2022 Q1	$7.23M	Buy	750,000 +650,000	+650%	+$5.53M	0.01%	782
2021 Q4	$1.19M	Buy	100,000 +50,000	+100%	+$703K	﹤0.01%	893
2021 Q3	$812K	Sell	50,000 -50,000	-50%	-$886K	﹤0.01%	921
2021 Q2	$2.1M	Buy	+100,000	New	+$1.88M	﹤0.01%	878

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Adage Capital Partners's DYN Position: Q1 2026 in Review

Adage Capital Partners reduced its Dyne Therapeutics (DYN) stake by 81% in Q1 2026, selling an estimated $71.9M and leaving 1,000,000 shares worth $18.1M. The position accounts for 0.03% of the portfolio, ranked #503.

Adage Capital Partners first reported a position in DYN in Q2 2021 and has held it in 17 quarters since. The position peaked at $117M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Adage Capital Partners held 1,000,000 shares of Dyne Therapeutics worth $18.1M as of Q1 2026.
Adage Capital Partners sold 4,172,000 Dyne Therapeutics shares in Q1 2026, an estimated $71.9M.
Dyne Therapeutics made up 0.03% of Adage Capital Partners's portfolio in Q1 2026, its #503 holding.
Adage Capital Partners first reported a position in Dyne Therapeutics in Q2 2021 and has held it in 17 quarters since.
Adage Capital Partners's Dyne Therapeutics position peaked at $117M in Q2 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.